Quick Answer
ADMA BIOLOGICS, INC. reported Total Revenue of $510.17 million for fiscal year 2025.
ADMA BIOLOGICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $510.17M +19.6% |
$426.45M +65.2% |
$258.21M +67.6% |
$154.08M +90.4% |
$80.94M +91.7% |
$42.22M +43.9% |
| Revenue (ASC 606) | $510.17M +19.6% |
$426.45M +65.2% |
$258.21M +67.6% |
$154.08M +90.4% |
$80.94M +91.7% |
$42.22M |
| Net Income | $146.93M -25.7% |
$197.67M +800.0% |
-$28.24M +57.2% |
-$65.90M +8.0% |
-$71.65M +5.4% |
-$75.75M -56.9% |
| Diluted EPS | $0.60 -25.9% |
$0.81 +723.1% |
-$0.13 +60.6% |
-$0.33 +35.3% |
-$0.51 +42.0% |
-$0.88 |
| Total Assets | $624.24M +27.7% |
$488.68M +48.5% |
$329.18M -5.5% |
$348.46M +26.1% |
$276.25M +33.0% |
$207.67M +63.4% |
| Cash and Equivalents | $87.63M -15.0% |
$103.15M +100.9% |
$51.35M -40.6% |
$86.52M +69.4% |
$51.09M -8.6% |
$55.92M +109.0% |
| Long-Term Debt | $69.33M -4.2% |
$72.34M | — | — | — | — |
| Stockholders Equity | $477.32M +36.8% |
$349.02M +158.1% |
$135.21M -11.0% |
$151.97M +7.7% |
$141.17M +60.0% |
$88.25M +236.9% |
| R&D Expense | $4.76M +162.7% |
$1.81M -45.1% |
$3.30M -8.7% |
$3.61M -0.9% |
$3.65M -38.3% |
$5.91M +490.7% |
| Operating Income | $191.44M +37.7% |
$138.98M +542.5% |
$21.63M +155.0% |
-$39.37M +32.6% |
-$58.37M +10.1% |
-$64.91M -56.7% |
| Gross Profit | $292.76M +33.3% |
$219.55M +146.8% |
$88.94M +152.2% |
$35.27M +2906.4% |
$1.17M +106.2% |
-$19.07M |
| Shares Outstanding | 237.87M +0.5% |
236.62M +4.7% |
226.06M +1.9% |
221.82M +13.3% |
195.81M +86.7% |
104.90M +76.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $134.22M | +12.0% | +10.0% |
| Revenue (ASC 606) | September 30, 2025 | $134.22M | +12.0% | +10.0% |
| Net Income | September 30, 2025 | $36.43M | +1.4% | +6.5% |
| Diluted EPS | September 30, 2025 | $0.15 | +0.0% | +7.1% |
| Total Assets | September 30, 2025 | $568.69M | +45.6% | +1.8% |
| Cash and Equivalents | September 30, 2025 | $61.38M | -29.2% | -32.0% |
| Long-Term Debt | September 30, 2025 | $70.08M | — | -3.1% |
| Stockholders Equity | September 30, 2025 | $431.19M | +85.9% | +8.2% |
| R&D Expense | September 30, 2025 | $1.53M | +270.9% | +48.2% |
| Operating Income | September 30, 2025 | $51.01M | +28.7% | +19.2% |
| Gross Profit | September 30, 2025 | $75.63M | +26.8% | +12.5% |
| Shares Outstanding | September 30, 2025 | 238.33M | +0.8% | -0.1% |
- ADMA BIOLOGICS, INC. reported Total Revenue of $510.17 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed an increase of +19.6% in Total Revenue compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Revenue (ASC 606) of $510.17 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed an increase of +19.6% in Revenue (ASC 606) compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Net Income of $146.93 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed a decrease of -25.7% in Net Income compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Diluted EPS of $0.60 per share for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed a decrease of -25.9% in Diluted EPS compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Total Assets of $624.24 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed an increase of +27.7% in Total Assets compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Cash and Equivalents of $87.63 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed a decrease of -15.0% in Cash and Equivalents compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Long-Term Debt of $69.33 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed a decrease of -4.2% in Long-Term Debt compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Stockholders Equity of $477.32 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed an increase of +36.8% in Stockholders Equity compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported R&D Expense of $4.76 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed an increase of +162.7% in R&D Expense compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Operating Income of $191.44 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed an increase of +37.7% in Operating Income compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Gross Profit of $292.76 million for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed an increase of +33.3% in Gross Profit compared to the prior fiscal year.
- ADMA BIOLOGICS, INC. reported Shares Outstanding of 237.87 million shares for fiscal year 2025.
- ADMA BIOLOGICS, INC. showed an increase of +0.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: